Endovia Health Sciences, Inc., formerly Splash Beverage Group, announced the establishment of Investigational New Animal Drug (INAD) File No. 14145 with the U.S. FDA for its CannEpil® veterinary development program. This milestone formally initiates regulatory engagement under a collaboration agreement with Lupvindal Biosciences Ltd. to develop CannEpil®, a cannabinoid formulation for managing cancer-related pain in companion animals, specifically targeting canine oncology. The company intends to pursue the FDA’s Minor Use / Minor Species (MUMS) designation and Conditional Approval pathway. Endovia Health Sciences operates as a diversified cannabinoid-based health sciences platform focused on pharmaceutical commercialization, FDA-regulated human and veterinary therapeutics, and consumer wellness.
